IT1254331B - Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico. - Google Patents

Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico.

Info

Publication number
IT1254331B
IT1254331B ITRM920305A ITRM920305A IT1254331B IT 1254331 B IT1254331 B IT 1254331B IT RM920305 A ITRM920305 A IT RM920305A IT RM920305 A ITRM920305 A IT RM920305A IT 1254331 B IT1254331 B IT 1254331B
Authority
IT
Italy
Prior art keywords
shock
cardiogen
treatment
pharmaceutical composition
septic
Prior art date
Application number
ITRM920305A
Other languages
English (en)
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to ITRM920305A priority Critical patent/IT1254331B/it
Publication of ITRM920305A0 publication Critical patent/ITRM920305A0/it
Priority to EP93106026A priority patent/EP0566971A1/en
Priority to JP5097534A priority patent/JPH069386A/ja
Publication of ITRM920305A1 publication Critical patent/ITRM920305A1/it
Application granted granted Critical
Publication of IT1254331B publication Critical patent/IT1254331B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La somministrazione per endovena di un bolo di 3-5 grammi di L-carnitina o di un suo sale farmacologicamente accettabile seguita da 3-5 grammi di L-carnitina o suo sale per infusione lenta in 12 ore circa, riportano drammaticamente ai valori di norma la pressione arteriosa e la frequenza respiratoria in un soggetto in grave stato di shock cardiogeno o settico.
ITRM920305A 1992-04-23 1992-04-23 Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico. IT1254331B (it)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ITRM920305A IT1254331B (it) 1992-04-23 1992-04-23 Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico.
EP93106026A EP0566971A1 (en) 1992-04-23 1993-04-14 Use of L-carnitine for the treatment of shock
JP5097534A JPH069386A (ja) 1992-04-23 1993-04-23 ショック症状の処置のための医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM920305A IT1254331B (it) 1992-04-23 1992-04-23 Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico.

Publications (3)

Publication Number Publication Date
ITRM920305A0 ITRM920305A0 (it) 1992-04-23
ITRM920305A1 ITRM920305A1 (it) 1993-10-23
IT1254331B true IT1254331B (it) 1995-09-14

Family

ID=11400966

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM920305A IT1254331B (it) 1992-04-23 1992-04-23 Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico.

Country Status (3)

Country Link
EP (1) EP0566971A1 (it)
JP (1) JPH069386A (it)
IT (1) IT1254331B (it)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3119430B2 (ja) * 1995-07-25 2000-12-18 大鵬薬品工業株式会社 水酸基ラジカル消去剤
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
US6090849A (en) * 1999-03-23 2000-07-18 The Board Of Regents For Oklahoma State University Carnitine supplemented diet to prevent sudden death syndrome in breeder type poultry
US10330685B2 (en) 2014-05-01 2019-06-25 The Regents Of The University Of Michigan Markers for sepsis treatment
KR102552942B1 (ko) 2015-11-24 2023-07-10 닛토 신코 가부시키가이샤 수지 조성물 및 전기 절연 시트
US12478603B2 (en) 2020-03-31 2025-11-25 The Regents Of The University Of Michigan Serum metabolites as biomarkers for carnitine treatment of sepsis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1184655B (it) * 1985-10-14 1987-10-28 Sigma Tau Ind Farmaceuti Imiego di acetil l-carnitina nel trattamento terapeutico degli stati di shock

Also Published As

Publication number Publication date
EP0566971A1 (en) 1993-10-27
ITRM920305A0 (it) 1992-04-23
ITRM920305A1 (it) 1993-10-23
JPH069386A (ja) 1994-01-18

Similar Documents

Publication Publication Date Title
KR100230514B1 (ko) 산화질소 형성 또는 내피 유도 이완 인자와 관련된 전신적 저혈압을 억제하기 위한 아르기닌 길항제
GR3031448T3 (en) Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine.
IL147852A0 (en) Chemokine receptor antagonists and pharmaceutical compositions containing the same
DK0854709T4 (da) Anvendelse af boswelliasyre og derivater deraf til hæmning af normal og foröget leukocytelastase- eller plasminaktivitet
IT1254331B (it) Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico.
IT1244636B (it) Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
NO931886L (no) Anvendelse av aica ribocid-forbindelser for behandling/prevensjon av vevskader som skyldes nedsatt blodstroemning
DE3687742D1 (de) Verwendung von acetyl-l-carnitin zur herstellung eines arzneimittels zur therapeutischen behandlung von schockzustaenden.
NO20042100D0 (no) Fremgangsmate for administrering av et tymosinalfa 1-peptid
Jacob et al. Prolongation of the QT interval in lithium toxicity
US5939404A (en) Cancer metastasis inhibitor containing a streptococcus agalactiae Ia type or Ib type surface polysaccharide as a main ingredient
WO1994002107A3 (en) Method and medicament for inhibiting neutrophil elastase and cathepsin g
RU95102611A (ru) Способ лечения туберкулеза легких
CA2205056A1 (en) Method for reducing the severity of gastro-intestinal damage
DE345883T1 (de) Verwendung von dapiprazol zur herstellung eines arzneimittels zur verhinderung des toleranzentwicklung bei der analgetischen behandlung mit morphin.
Káldor et al. Enhancement of methyldopa metabolism with barbiturate
UA32868A (uk) Спосіб лікування резистивної форми епілепсії
Watson et al. Management of massive verapamil overdose
RU96104214A (ru) Способ лечения транссудативных форм центральных хориоретинальных дистрофий
Thompson et al. Furadantin: a reassessment in the light of excretion studies
UA36043A (uk) Спосіб лікування фетоплацентарної недостатності
McAllister Local Anesthetic Systemic Toxicity or Vasovagal Syncope?
UA15281A (uk) Спосіб лікуваhhя хроhічhої ішемічhої хвороби серця
UA10301A (uk) Спосіб лікуваhhя раку шлуhку
Engrand et al. About intrathecal baclofen in tetanus/About intrathecal baclofen in tetanus--Reply